A fully synthetic immunogen carrying a carcinoma-associated carbohydrate for active specific immunotherapy

Cancer Research

Volumn 59, Issue 7, 1999, Pages 1520-1524

  Lo Man, Richard ^a,b   Bay, Sylvie ^a   Vichier Guerre, Sophie ^a   Dériaud, Edith ^a   Cantacuzène, Danièle ^a   Leclerc, Claude ^a  

^a INSTITUT PASTEUR   (France)

^b U de Biol des Reg Immunitaires   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE DERIVATIVE; CD4 ANTIGEN; EPITOPE; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER TRANSPLANTATION; CONTROLLED STUDY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; NEOPLASMS, EXPERIMENTAL; TUMOR CELLS, CULTURED;

EID: 0033118481     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Springer, G. F. T and Tn, general carcinoma autoantigens. Science (Washington DC), 224: 1198-1206, 1984.
2. MacLean, G. D., Reddish, M., Koganty, R. R., Wong, T., Gandhi, S., Smolenski, M., Samuel, J., Nabholtz, J. M., and Longenecker, B. M. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol. Immunother., 36: 215-222, 1993.
3. Toyokuni, T., Hakomori, S., and Singhal, A. K. Synthetic carbohydrate vaccines: synthesis and immunogenicity of Tn antigen conjugates. Bioorg. Med. Chem., 2: 1119-1132, 1994.
4. Deshpande, P. P., and Danishefsky, S. J. Total synthesis of the potential anticancer vaccine kh-1 adenocarcinoma antigen. Nature (Lond.), 387: 164-166, 1997.
5. Sames, D., Chen, X. T., and Danishefsky, S. J. Convergent total synthesis of a tumour-associated mucin motif. Nature (Lond.), 389: 587-591, 1997.
6. Kim, Y. J., and Varki, A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj. J., 14: 569-576, 1997.
7. Kitamura, K., Stockert, E., Garin-Chesa, P., Welt, S., Lloyd, K. O., Armour, K. L., Wallace, T. P., Harris, W. J., Carr, F. J., and Old, L. J. Specificity analysis of blood group Lewis-y (Le(y)) antibodies generated against synthetic and natural Le(y) determinants. Proc. Natl. Acad. Sci. USA, 91: 12957-12961, 1994.
8. Helling, F., Zhang, S., Shang, A., Adluri, S., Calves, M., Koganty, R., Longenecker, B. M., Yao, T. J., Oettgen, H. F., and Livingston, P. O. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res., 55: 2783-2788, 1995.
9. Herzenberg, L. A., Tokuhisa, T., and Herzenberg, L. A. Carrier-priming leads to hapten-specific suppression. Nature (Lond.), 285: 664-667, 1980.
10. Schutze, M. P., Leclerc, C., Jolivet, M., Audibert, F., and Chedid, L. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J. Immunol., 135: 2319-2322, 1985.
11. Bay, S., Lo-Man, R., Osinaga, E., Nakada, H., Leclerc, C., and Cantacuzène, D. Preparation of a multiple antigen glycopeptide (MAG) carrying the Tn antigen: a possible approach to a synthetic carbohydrate vaccine. J. Pept. Res., 49: 620-625, 1997.
12. Lemieux, R. U., and Ratcliffe, R. M. The azidonitration of tri-O-acetyl-D-galactal. Can. J. Chem., 47: 1244-1251, 1979.
13. Ferrari, B., and Pavia, A. A. The synthesis of derivatives of 3-O-(2-acetamido-2-deoxy-α-D-galactopyranosyl)-L-serine and -L-threonine. Carbohydr. Res., 79: C1-C7, 1980.
14. Lo-Man, R., Martineau, P., Manoury-Schwartz, B., Hofnung, M., and Leclerc, C. Overcoming the crypticity of a viral T cell determinant by insertion into a bacterial chimeric protein. Int. Immunol., 8: 1245-1255, 1996.
15. Numata, Y., Nakada, H., Fukui, S., Kitagawa, H., Ozaki, K., Inoue, M., Kawasaki, T., Funakoshi, I., and Yamashina, I. A monoclonal antibody directed to Tn antigen. Biochem. Biophys. Res. Commun., 170: 981-985, 1990.
16. Deck, B., Elofsson, M., Kihlberg, J., and Unanue, E. R. Specificity of glycopeptide-specific T cells. J. Immunol., 155: 1074-1078, 1995.
17. Jensen, T., Hansen, P., Galli-Stampino, L., Mouritsen, S., Frische, K., Meinjohanns, E., Meldal, M., and Werdelin, O. Carbohydrate and peptide specificity of MHC class II-restricted T cell hybridomas raised against an O-glycosylated self peptide. J. Immunol., 158: 3769-3778, 1997.
18. Nakada, H., Numata, Y., Inoue, M., Tanaka, N., Kitagawa, H., Funakoshi, I., Fukui, S., and Yamashina, I. Elucidation of an essential structure recognized by an anti-GalNAc α-Ser(Thr) monoclonal antibody (MLS 128). J. Biol. Chem., 266: 12402-12405, 1991.
19. Nakada, H., Inoue, M., Numata, Y., Tanaka, N., Funakoshi, I., Fukui, S., Mellors, A., and Yamashina, I. Epitopic structure of Tn glycophorin A for an anti-Tn antibody (MLS 128). Proc. Natl. Acad. Sci. USA, 90: 2495-2499, 1993.
20. Nakada, H., Inoue, M., Tanaka, N., Numata, Y., Kitagawa, H., Fukui, S., and Yamashina, I. Expression of the Tn antigen on T-lymphoid cell line Jurkat. Biochem. Biophys. Res. Commun. 179: 762-767, 1991.
21. Fung, P. Y., Madej, M., Koganty, R. R., and Longenecker, B. M. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res., 50: 4308-4314, 1990.
22. Singhal, A., Fohn, M., and Hakomori, S. Induction of α-N-acetylgalactosamine-O-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice. Cancer Res., 51: 1406-1411, 1991.
23. Van den Eijnden, D. H., Evans, N. A., Codington, J. F., Reinhold, V., Silber, C., and Jeanloz, R. W. Chemical structure of epiglycanin, the major glycoprotein of the TA3-Ha ascites cell. The carbohydrate chains. J. Biol. Chem., 254: 12153-12159, 1979.
24. Hauschka, T. S., Weiss, L., Holdridge, B. A., Cudney, T. L., Zumpft, M., and Planinsek, J. A. Karyotypic ard surface features of murine TA3 carcinoma cells during immunoselection in mice and rats. J. Natl. Cancer Inst. (Bethesda), 47: 343-359, 1971.
25. Adluri, S., Helling, F., Ogata, S., Zhang, S., Itzkowitz, S. H., Lloyd, K. O., and Livingston, P. O. Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients. Cancer Immunol. Immunother., 41: 185-192, 1995.
26. Reddish, M. A., MacLean, G. D., Poppema, S., Berg, A., and Longenecker, B. M. Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol. Immunother., 42: 303-309, 1996.
27. Chong, P., Chan, N., Kandil, A., Tripet, B., James, O., Yang, Y. P., Shi, S. P., and Klein, M. A strategy for rational design of fully synthetic glycopeptide conjugate vaccines. Infect. Immun., 65: 4918-4925, 1997.
28. Haurum, J. S., Arsequell, G., Lellouch, A. C., Wong, S. Y. C., Dwek, R. A., McMichael, A. J., and Elliott, T. Recognition of carbohydrate by MHC complex class I-restricted, glycopeptide-specific T lymphocytes. J. Exp. Med., 180: 739-744, 1994.
29. Zhang, S., Walberg, L. A., Ogata, S., Itzkowitz, S. H., Koganty, R. R., Reddish, M., Gandhi, S. S., Longenecker, B. M., Lloyd, K. O., and Livingston, P. O. Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen. Cancer Res., 55: 3364-3368, 1995.
30. Kuduk, S. D., Schwarz, J. B., Chen, X. T., Glunz, P. W., Sames, D., Ragupathi, G., Livingston, P. O., and Danishefsky, S. J. Synthetic and immunological studies on clustered modes of mucin-related Tn and TF O-linked antigens: the preparation of a glycopeptide-based vaccine for clinical trials against prostate cancer. J. Am. Chem. Soc., 120: 12474-12485, 1998.
31. Ogata, S., Koganty, R., Reddish, M., Longenecker, B. M., Chen, A. L., Perez, C., and Itzkowitz, S. H. Different modes of sialyl-Tn expression during malignant transformation of human coloni mucosa. Glycoconj. J., 15: 29-35, 1998.
32. Livingston, P. O. Augmenting the immunogenicity of carbohydrate tumor antigens. Semin. Cancer Biol., 6: 357-366, 1995.
33. Panina-Bordignon, P., Tan, A., Termijtelen, A., Demotz, S., Corradin, G., and Lanzavecchia, A. Universal immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J. Immunol., 19: 2237-2242, 1989.
34. Reece, J. C., Geysen, H. M., and Rodda, S. J. Mapping the major human T helper epitopes of tetanus toxin. The emerging picture. J. Immunol., 151: 6175-6184, 1993.
35. Etlinger, H. M., Gillessen, D., Lahm, H. W., Matile, H., Schonfeld, H. J., and Trzeciak, A Use of prior vaccinations for the development of new vaccines. Science (Washington DC), 249: 423-425, 1990.
36. Franke, E. D., Corradin, G., and Hoffman, S. L. Induction of protective CTL responses against the P. yoelii cicumsporozoite protein by immunization with peptides. J. Immunol., 159: 3424-3433, 1997.
37. Goydos, J. S., Elder, E., Whiteside, T. L., Finn, O. J., and Lotze, M. T. A Phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients vvitn adenocarcinoma. J. Surg. Res., 63: 298-304, 1996.